Global Psoriasis Treatment Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Psoriasis Treatment Market Size

• The global psoriasis treatment market size was valued at USD 29.20 billion in 2025 and is expected to reach USD 53.44 billion by 2033, at a CAGR of 7.85% during the forecast period
• The market growth is largely fueled by the growing prevalence of psoriasis worldwide, rising awareness of treatment options, and rapid adoption of advanced biologic and targeted therapies that offer improved efficacy and safety profiles
• Furthermore, increasing diagnosis rates, expanding R&D investments, and consumer demand for personalized and effective treatment solutions are establishing innovative therapeutic options as the preferred management strategy for patients. These converging factors are accelerating uptake of psoriasis treatment solutions, thereby significantly boosting the industry’s growth

Psoriasis Treatment Market Analysis

• Psoriasis treatments, encompassing corticosteroids, TNF inhibitors, interleukins, and other drug classes, are increasingly vital components of modern dermatological care due to their effectiveness in managing chronic symptoms, improving patient quality of life, and preventing disease progression
• The escalating demand for psoriasis treatments is primarily fueled by the rising prevalence of plaque psoriasis and psoriatic arthritis globally, growing awareness of available therapies, and an increasing preference for advanced systemic and combination treatment options that offer improved efficacy and safety
• North America dominated the psoriasis treatment market with the largest revenue share of 38.5% in 2025, characterized by high healthcare spending, early adoption of parenteral biologic therapies, and a strong presence of leading pharmaceutical companies, with the U.S. experiencing substantial growth in treatment uptake driven by innovations in interleukin-targeting agents
• Asia-Pacific is expected to be the fastest growing region in the psoriasis treatment market during the forecast period due to increasing healthcare access, rising disposable incomes, and expanding distribution through hospitals, clinics, retail pharmacies, and online sales channels
• Parenteral segment dominated the market with a market share of 46.7% in 2025, driven by the high adoption of injectable biologics that provide superior disease control and long-term treatment outcomes compared to traditional oral and topical therapies

Report Scope and Psoriasis Treatment Market Segmentation

Psoriasis Treatment Market Trends

“Shift Towards Biologics and Targeted Therapies”

• A significant and accelerating trend in the global psoriasis treatment market is the growing adoption of biologics and targeted therapies, which provide improved efficacy, fewer side effects, and long-term disease control for moderate-to-severe psoriasis patients
• For instance, Cosentyx (secukinumab) has shown high efficacy in treating plaque psoriasis and psoriatic arthritis, gaining widespread physician preference and patient acceptance across multiple regions
• Targeted therapies enable precise modulation of the immune system, such as interleukin inhibitors reducing inflammation while minimizing systemic exposure, thereby offering safer treatment options
• The integration of biologics with personalized treatment plans based on genetic profiling and disease severity allows dermatologists to optimize therapeutic outcomes and minimize trial-and-error approaches
• This trend towards more advanced, precise, and patient-specific therapies is fundamentally reshaping treatment expectations, with companies such as AbbVie and Novartis launching newer interleukin-targeting biologics to address unmet patient needs
• The demand for effective, long-lasting, and safer therapies is growing rapidly across both hospital and outpatient settings, as patients increasingly prioritize quality of life and sustained disease management
• Rising interest in combination therapies, which integrate biologics with topical or systemic drugs, is offering dermatologists flexible treatment options to manage refractory or complex psoriasis cases

Psoriasis Treatment Market Dynamics

Driver

“Rising Prevalence and Increasing Awareness of Psoriasis”

• The increasing prevalence of psoriasis worldwide, coupled with growing patient and physician awareness of advanced treatment options, is a significant driver for heightened demand in the market
• For instance, in 2025, AbbVie expanded its global distribution of Skyrizi (risankizumab) to address rising moderate-to-severe plaque psoriasis cases, highlighting the role of biologics in driving market growth
• As more patients are diagnosed and seek treatment, systemic and biologic therapies offer superior disease control compared to traditional topical treatments, providing a compelling option for dermatologists and patients
• Furthermore, increasing access to healthcare services, awareness campaigns, and patient support programs are making advanced therapies more widely accepted and adopted globally
• The convenience of self-administered injectable therapies, combined with improved patient adherence and efficacy monitoring through clinics and telemedicine, is key to market expansion
• Government initiatives and health insurance coverage improvements in major markets are facilitating patient access to expensive biologic therapies, further driving adoption rates
• Rising research and development investments by pharmaceutical companies are continuously introducing new therapies, expanding treatment portfolios, and creating additional growth opportunities
• Collaborations between dermatology centers, hospitals, and patient advocacy groups are increasing awareness and early diagnosis, which in turn boosts demand for effective treatments

Restraint/Challenge

“High Treatment Costs and Limited Accessibility”

• The high cost of biologics and advanced systemic therapies, coupled with insurance coverage limitations, poses a significant challenge to broader market penetration, particularly in developing regions
• For instance, many patients in low- and middle-income countries are unable to access interleukin inhibitors due to prohibitive costs, limiting treatment adoption despite high efficacy
• Addressing affordability through patient assistance programs, biosimilar launches, and government healthcare initiatives is crucial for improving accessibility and expanding the patient base
• In addition, treatment side effects, such as increased risk of infections with immunosuppressive therapies, create patient hesitancy and require careful monitoring by healthcare providers
• While advances in treatment options are increasing, the combination of cost barriers and safety concerns can hinder widespread adoption and market growth
• Overcoming these challenges through improved insurance coverage, development of cost-effective biosimilars, and patient education on safety management will be vital for sustained market expansion
• Limited infrastructure for cold-chain storage and delivery of biologics in certain regions can restrict availability, further challenging market penetration
• Stringent regulatory approvals and variations in drug reimbursement policies across countries can delay launch of new therapies, affecting market growth momentum

Psoriasis Treatment Market Scope

The market is segmented on the basis of drug class, type, route of administration, application, and end user.

•  By Drug Class

On the basis of drug class, the psoriasis treatment market is segmented into corticosteroids, TNF inhibitors, interleukins, and others. The interleukins segment dominated the market with the largest revenue share of 45% in 2025, driven by their targeted action against specific inflammatory pathways, resulting in higher efficacy and fewer systemic side effects. Interleukin inhibitors are widely prescribed for moderate-to-severe plaque psoriasis and psoriatic arthritis, offering sustained disease control. Physicians often favor interleukins for patients who do not respond to traditional therapies or TNF inhibitors. The segment’s growth is also supported by increasing approvals of newer interleukin-targeting biologics by regulatory authorities. Patient adherence is enhanced due to convenient dosing schedules, such as monthly or bi-monthly injections. The combination of clinical efficacy, patient convenience, and strong physician adoption makes interleukins the largest revenue-generating drug class in the market.

The TNF inhibitors segment is expected to witness the fastest growth rate of 12.8% CAGR from 2026 to 2033, fueled by rising adoption in emerging markets and expansion of insurance coverage. TNF inhibitors are effective for both psoriasis and psoriatic arthritis, increasing their utility in multi-symptom management. Growing awareness among patients and dermatologists about early intervention benefits is boosting TNF inhibitor uptake. Biosimilar launches are improving affordability, further expanding market access. The segment benefits from established clinical data supporting long-term safety and efficacy, encouraging both physicians and patients to prefer TNF inhibitors. Increasing R&D investments by key pharmaceutical companies are expected to introduce next-generation TNF inhibitors, further propelling growth.

• By Type

On the basis of type, the psoriasis treatment market is segmented into plaque psoriasis, psoriatic arthritis, and others. The plaque psoriasis segment dominated the market with a revenue share of 58% in 2025, as it represents the most common manifestation of the disease affecting a majority of patients. Treatments for plaque psoriasis include topical therapies, systemic drugs, and biologics, making it a major contributor to overall market revenue. Dermatologists prefer targeted therapies for moderate-to-severe plaque psoriasis due to higher efficacy and improved patient adherence. Patient awareness campaigns and early diagnosis programs have also increased the treatment rate for plaque psoriasis. The chronic nature of the disease requires long-term therapy, sustaining recurring demand. Pharmaceutical companies are continuously innovating formulations to improve convenience and outcomes, further supporting market dominance.

The psoriatic arthritis segment is expected to witness the fastest CAGR of 11.5% from 2026 to 2033, driven by rising diagnosis rates and increasing adoption of systemic and biologic therapies. Psoriatic arthritis can cause joint damage if untreated, prompting higher physician intervention. Awareness among patients about the benefits of early treatment is growing, especially in developed markets. Combination therapies targeting both skin and joint symptoms are gaining traction, boosting treatment uptake. Market growth is further supported by increasing access to specialty care clinics and insurance coverage for biologics. Pharmaceutical innovations focusing on dual-action therapies for skin and joint manifestations enhance the segment’s growth potential.

• By Route of Administration

On the basis of route of administration, the market is segmented into oral, parenteral, and topical. The parenteral segment dominated the market with a share of 46.7% in 2025, driven by the high adoption of injectable biologics and interleukin inhibitors that provide superior disease control. Parenteral therapies are often preferred for moderate-to-severe cases and for patients unresponsive to oral or topical treatments. Injections offer controlled dosing and longer intervals between administrations, improving patient adherence. Clinics and hospitals widely administer parenteral therapies due to monitoring requirements. Biologics delivered parenterally are supported by clinical evidence demonstrating long-term efficacy and safety. The growth is further aided by patient preference for less frequent dosing and better management of chronic symptoms.

The oral segment is expected to witness the fastest CAGR of 10.9% from 2026 to 2033, fueled by the convenience of pill-based administration and the increasing availability of small-molecule therapies. Oral treatments are easier for patients to self-administer, enhancing adherence. New oral therapies targeting specific inflammatory pathways are being approved, increasing clinical adoption. Patients with mild-to-moderate psoriasis prefer oral drugs due to convenience and lower invasiveness compared to injections. Rising awareness among dermatologists about oral treatment efficacy is driving prescription rates. Emerging markets are increasingly adopting oral therapies due to improved affordability and distribution access.

• By Application

On the basis of application, the market is segmented into topical therapeutic drugs, systemic therapeutic drugs, and combinations. The systemic therapeutic drugs segment dominated the market with a revenue share of 52% in 2025, driven by the high prevalence of moderate-to-severe psoriasis cases requiring systemic intervention. Systemic drugs, including biologics and oral therapies, offer comprehensive disease management and improved long-term outcomes. Physicians prefer systemic therapies for patients with extensive lesions or joint involvement. Recurrent usage and continuous monitoring contribute to sustained revenue generation. Increased insurance coverage and patient awareness programs have accelerated systemic therapy adoption. Pharmaceutical companies are focusing on next-generation systemic therapies with enhanced safety profiles, reinforcing market leadership.

The combination therapies segment is expected to witness the fastest CAGR of 13.2% from 2026 to 2033, fueled by the need to manage complex cases using multi-mechanism approaches. Combination therapy integrates topical, systemic, and biologic treatments to maximize efficacy. Patients with refractory or severe psoriasis benefit from tailored combination regimens. Rising research on synergistic effects of combination therapies is boosting physician confidence. Healthcare providers are increasingly adopting combination approaches to reduce relapse rates and improve patient quality of life. The growing prevalence of difficult-to-treat cases is supporting the adoption of combination therapy globally.

• By End User

On the basis of end user, the market is segmented into hospital pharmacy, clinics, retail pharmacies, and online sales. The hospital pharmacy segment dominated the market with a revenue share of 41% in 2025, driven by the administration of biologics, systemic therapies, and parenteral drugs under professional supervision. Hospitals offer treatment monitoring, patient education, and adherence programs, which are critical for chronic management. Specialist dermatology centers within hospitals provide access to advanced therapies and early diagnosis. Hospital pharmacies benefit from recurring prescriptions and institutional procurement contracts, supporting revenue growth. Insurance reimbursements and hospital partnerships enhance affordability and access. Hospitals remain the preferred channel for moderate-to-severe cases, reinforcing dominance.

The online sales segment is expected to witness the fastest CAGR of 15.5% from 2026 to 2033, fueled by increasing e-pharmacy adoption, convenience, and home delivery services. Online platforms allow patients to access medications discreetly, including prescription fulfillment for oral and topical drugs. Telemedicine integration is further driving online pharmacy growth. Online sales improve access in remote or underserved regions, enhancing patient compliance. E-commerce discounts and subscription models attract cost-sensitive patients. Rising digital literacy and smartphone penetration accelerate market expansion through online channels.

Psoriasis Treatment Market Regional Analysis

• North America dominated the psoriasis treatment market with the largest revenue share of 38.5% in 2025, characterized by high healthcare spending, early adoption of parenteral biologic therapies, and a strong presence of leading pharmaceutical companies
• Patients and healthcare providers in the region prioritize effective, long-term treatment options such as interleukin inhibitors and TNF inhibitors, supported by strong clinical evidence and established treatment guidelines
• Cette adoption généralisée est également favorisée par une infrastructure de soins de santé bien développée, une forte sensibilisation aux options de prise en charge du psoriasis, la couverture d'assurance des traitements coûteux et l'accès à des cliniques de dermatologie spécialisées, faisant des biothérapies et des traitements systémiques les solutions thérapeutiques privilégiées pour les cas modérés à sévères, tant en milieu hospitalier qu'ambulatoire.

Aperçu du marché américain des traitements contre le psoriasis

Le marché américain des traitements du psoriasis a représenté 82 % des revenus en Amérique du Nord en 2025, porté par la prévalence croissante du psoriasis modéré à sévère et l'adoption généralisée des biothérapies et des thérapies ciblées. Patients et professionnels de santé privilégient de plus en plus la prise en charge à long terme de la maladie grâce aux traitements par inhibiteurs d'interleukine et de TNF. La préférence grandissante pour un diagnostic précoce et des plans de traitement personnalisés, conjuguée à une couverture d'assurance étendue et à la présence de cliniques dermatologiques spécialisées, dynamise davantage le marché. Par ailleurs, les programmes de sensibilisation des patients et les investissements en R&D des principaux laboratoires pharmaceutiques contribuent significativement à son expansion.

Analyse du marché européen des traitements du psoriasis

Le marché européen des traitements du psoriasis devrait connaître une croissance annuelle composée (TCAC) importante tout au long de la période de prévision, principalement grâce à une meilleure connaissance des options thérapeutiques avancées et à des réglementations sanitaires plus strictes. L'urbanisation croissante et la demande accrue de prise en charge efficace des maladies chroniques favorisent l'adoption des biothérapies et des traitements systémiques. Les patients et les médecins européens privilégient les thérapies personnalisées, conformes aux recommandations, qui offrent une efficacité supérieure et moins d'effets secondaires. La région connaît une forte croissance dans les hôpitaux, les cliniques et les pharmacies, les biothérapies étant de plus en plus intégrées aux protocoles de traitement des nouveaux patients comme des patients déjà suivis.

Analyse du marché britannique des traitements contre le psoriasis

Le marché britannique des traitements du psoriasis devrait connaître une croissance annuelle composée (TCAC) remarquable au cours de la période de prévision, portée par une sensibilisation accrue des patients, une forte adoption des biothérapies et une infrastructure de santé performante. Par ailleurs, les initiatives de diagnostic précoce et les préoccupations liées à l'évolution de la maladie incitent patients et professionnels de santé à privilégier les thérapies systémiques avancées. La couverture d'assurance maladie étendue au Royaume-Uni, associée à un accès facilité aux dermatologues et aux pharmacies en ligne, devrait continuer à stimuler la croissance du marché. Le recours aux thérapies combinées pour la prise en charge des cas réfractaires contribue également à son expansion.

Analyse du marché allemand des traitements contre le psoriasis

Le marché allemand des traitements du psoriasis devrait connaître une croissance annuelle composée (TCAC) importante au cours de la période de prévision, portée par une sensibilisation accrue aux thérapies personnalisées et par un système de santé performant. L'infrastructure développée du pays, l'importance accordée à la recherche clinique et la priorité donnée aux soins centrés sur le patient favorisent l'adoption des biothérapies et des traitements systémiques. L'intégration des services de télédermatologie et des consultations spécialisées se généralise également, les patients privilégiant les thérapies de pointe offrant un contrôle durable de la maladie et une sécurité accrue. Des programmes innovants d'accès aux traitements contribuent à leur adoption, tant en milieu hospitalier qu'ambulatoire.

Aperçu du marché des traitements du psoriasis en Asie-Pacifique

Le marché des traitements du psoriasis en Asie-Pacifique devrait connaître la croissance annuelle composée la plus rapide (23 %) entre 2026 et 2033, portée par la prévalence croissante de la maladie, une meilleure sensibilisation aux soins de santé et un accès facilité aux thérapies de pointe dans des pays comme la Chine, le Japon et l'Inde. L'adoption croissante des biothérapies, les initiatives gouvernementales en matière de santé et le développement des infrastructures de soins contribuent à cette croissance. Par ailleurs, la disponibilité de biosimilaires et de traitements systémiques abordables élargit l'accès aux soins à un plus grand nombre de patients. Enfin, la sensibilisation accrue des patients et la multiplication des centres de dermatologie spécialisés favorisent également l'adoption de ces traitements en milieu hospitalier et ambulatoire.

Analyse du marché japonais des traitements contre le psoriasis

Le marché japonais des traitements du psoriasis est en plein essor grâce à une forte sensibilisation aux biothérapies, à un système de santé performant et à une priorité accordée à la qualité de vie des patients. L'adoption de thérapies avancées est stimulée par l'augmentation des cas de psoriasis modéré à sévère et l'intégration croissante de la télédermatologie et du suivi en clinique. Le vieillissement de la population devrait accroître la demande de traitements pratiques et efficaces. Par ailleurs, l'accent mis au Japon sur le diagnostic précoce, la prévention et les thérapies personnalisées favorise la croissance du marché, tant en milieu hospitalier qu'ambulatoire.

Analyse du marché indien des traitements du psoriasis

En 2025, le marché indien des traitements contre le psoriasis représentait la plus grande part de revenus de la région Asie-Pacifique, grâce à une prévalence croissante, un meilleur accès aux soins et une adoption accrue des biothérapies et des traitements systémiques. L'Inde compte un grand nombre de patients atteints de psoriasis, et les programmes de sensibilisation contribuent à améliorer les taux de diagnostic précoce. Le développement des initiatives de santé numérique, la disponibilité de biosimilaires abordables et l'expansion des cliniques de dermatologie spécialisées sont des facteurs clés de la croissance de ce marché. Par ailleurs, l'urbanisation croissante, la hausse des revenus disponibles et l'amélioration de la couverture d'assurance maladie facilitent l'accès aux traitements et favorisent leur adoption dans les hôpitaux, les cliniques et les pharmacies.

Part de marché du traitement du psoriasis

Le secteur du traitement du psoriasis est principalement dominé par des entreprises bien établies, notamment :

• AbbVie Inc (États-Unis)
• Amgen Inc. (États-Unis)
• Eli Lilly and Company (États-Unis)
• Pfizer Inc. (États-Unis)
• Services Johnson & Johnson, Inc. (États-Unis)
• Novartis AG (Suisse)
• Société pharmaceutique Takeda Limitée (Japon)
• Biogen Inc. (États-Unis)
• Sanofi (France)
• Merck & Co., Inc., (États-Unis)
• Bristol‑Myers Squibb Company, (États-Unis)
• Celgene Corporation (États-Unis)
• Sun Pharmaceutical Industries Ltd., (Inde)
• Teva Pharmaceutical Industries Ltd., (Israël)
• Alvotech hf. (Islande)
• Protagonist Therapeutics, Inc., (États-Unis)
• Roivant Sciences Ltd., (États-Unis)
• Organon & Co., (États-Unis)
• Laboratoires Stiefel, Inc. (États-Unis)
• Horizon Therapeutics plc (Irlande)

Quels sont les développements récents sur le marché mondial du traitement du psoriasis ?

• En décembre 2025, Takeda a révélé que son médicament oral expérimental zasocitinib, conçu grâce à l'IA, avait permis d'obtenir des résultats cutanés significativement meilleurs dans deux essais de phase avancée pour le psoriasis en plaques, le positionnant comme un concurrent potentiel sérieux aux traitements oraux et injectables existants en attendant les demandes d'autorisation de mise sur le marché.
• En septembre 2025, la FDA américaine a approuvé TREMFYA® (guselkumab) pour les patients pédiatriques âgés de six ans et plus atteints de psoriasis en plaques modéré à sévère et d'arthrite psoriasique active, devenant ainsi le premier inhibiteur de l'IL-23 à bénéficier de cette indication élargie et offrant de nouvelles options de traitement aux patients plus jeunes.
• En octobre 2023, la Food and Drug Administration américaine a approuvé le BIMZELX® (bimekizumab-bkzx), le premier médicament biologique spécifiquement conçu pour inhiber à la fois l'IL-17A et l'IL-17F, pour le traitement des adultes atteints de psoriasis en plaques modéré à sévère, ce qui représente une avancée significative dans l'immunothérapie ciblée de cette maladie.
• En octobre 2023, la FDA américaine a approuvé la version biosimilaire d'Amgen du Stelara (ustekinumab) de Johnson & Johnson, élargissant ainsi l'accès à une option biologique moins coûteuse pour le psoriasis en plaques et les affections inflammatoires apparentées, une décision qui devrait influencer les prix et l'accessibilité.
• En septembre 2022, la FDA américaine a approuvé Sotyktu™ (deucravacitinib), le premier inhibiteur oral de TYK2 pour le psoriasis en plaques modéré à sévère, représentant un changement majeur vers des alternatives de traitement oral efficaces aux côtés des produits biologiques injectables.

SKU-26330